-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
New treatments for neurogenic detrusor overactivity
Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
Clinical Trail Outcomes: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
Clinical trial success influenced by biomarker- and receptor-targeted therapies
News and Views: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
A close look at trachoma control and the challenges that district programs pose
Sheila West
Editorial: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Pharmacodynamic end points in early phase oncology trials
Giovanna Speranza, James H Doroshow, Shivaani Kummar
Clinical Trail Perspective: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation
-
Diabetes vaccines: review of the clinical evidence
Johnny Ludvigsson
Review Article: Clinical Investigation